DK1731605T3 - Cancerantigenpeptider der er afledt af WT1 - Google Patents
Cancerantigenpeptider der er afledt af WT1Info
- Publication number
- DK1731605T3 DK1731605T3 DK05727848.3T DK05727848T DK1731605T3 DK 1731605 T3 DK1731605 T3 DK 1731605T3 DK 05727848 T DK05727848 T DK 05727848T DK 1731605 T3 DK1731605 T3 DK 1731605T3
- Authority
- DK
- Denmark
- Prior art keywords
- peptides derived
- cancer antigen
- antigen peptides
- peptide
- cancer
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 108010080347 HLA-A*26 antigen Proteins 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004105219 | 2004-03-31 | ||
PCT/JP2005/006113 WO2005095598A1 (ja) | 2004-03-31 | 2005-03-30 | Wt1由来の癌抗原ペプチド |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1731605T3 true DK1731605T3 (da) | 2010-05-25 |
Family
ID=35063778
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10152702.6T DK2186896T3 (da) | 2004-03-31 | 2005-03-30 | Cancerantigenpeptider afledt fra WT1 |
DK05727848.3T DK1731605T3 (da) | 2004-03-31 | 2005-03-30 | Cancerantigenpeptider der er afledt af WT1 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10152702.6T DK2186896T3 (da) | 2004-03-31 | 2005-03-30 | Cancerantigenpeptider afledt fra WT1 |
Country Status (12)
Country | Link |
---|---|
US (3) | US7622119B2 (da) |
EP (2) | EP2186896B1 (da) |
JP (1) | JP4886507B2 (da) |
AT (1) | ATE462003T1 (da) |
DE (1) | DE602005020121D1 (da) |
DK (2) | DK2186896T3 (da) |
ES (2) | ES2556232T3 (da) |
HK (1) | HK1144305A1 (da) |
PL (1) | PL1731605T3 (da) |
PT (1) | PT1731605E (da) |
SI (1) | SI1731605T1 (da) |
WO (1) | WO2005095598A1 (da) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000006602A1 (fr) * | 1998-07-31 | 2000-02-10 | Haruo Sugiyama | Antigenes contre le cancer a base d'un produit du gene suppresseur de tumeur wt1 |
BRPI0208183B8 (pt) | 2001-03-22 | 2021-05-25 | Sugiyama Haruo | peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer |
US8735357B2 (en) * | 2001-09-28 | 2014-05-27 | International Institute Of Cancer Immunology, Inc. | Method of inducing antigen-specific T cells |
EP1550453B1 (en) * | 2002-09-12 | 2015-05-27 | International Institute of Cancer Immunology, Inc. | Cancer antigen peptide preparation |
AU2004204031B2 (en) | 2003-01-15 | 2010-03-04 | International Institute Of Cancer Immunology, Inc. | Dimerized peptide |
KR101292971B1 (ko) * | 2003-06-27 | 2013-08-12 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Wt1 백신 적응 환자의 선택 방법 |
CN100513563C (zh) | 2003-11-05 | 2009-07-15 | 株式会社国际癌症免疫研究所 | Wt1衍生的hla-dr-结合抗原肽 |
WO2005095598A1 (ja) * | 2004-03-31 | 2005-10-13 | International Institute Of Cancer Immunology, Inc. | Wt1由来の癌抗原ペプチド |
CA2626238C (en) | 2005-10-17 | 2015-10-06 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
AU2006319892B2 (en) * | 2005-11-30 | 2012-05-10 | International Institute Of Cancer Immunology, Inc. | Novel peptide compound |
DK1988163T3 (da) * | 2006-02-22 | 2012-08-20 | Int Inst Cancer Immunology Inc | Hla-a*3303-begrænset wt1 peptid og farmaceutisk sammensætning omfattende det samme |
US9265816B2 (en) | 2006-04-10 | 2016-02-23 | Sloan Kettering Institute For Cancer Research | Immunogenic WT-1 peptides and methods of use thereof |
ES2629578T3 (es) | 2006-12-28 | 2017-08-11 | International Institute Of Cancer Immunology, Inc. | Péptido WT1 restringido a HLA-A*1101 y una composición farmacéutica que comprenden el mismo |
AU2008220031B2 (en) * | 2007-02-27 | 2013-06-13 | International Institute Of Cancer Immunology, Inc. | Method for activation of helper T cell and composition for use in the method |
MX343633B (es) | 2007-03-05 | 2016-11-11 | Int Inst Cancer Immunology Inc | Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos. |
WO2009066462A1 (ja) * | 2007-11-20 | 2009-05-28 | Nec Corporation | 細胞傷害性t細胞の誘導方法、細胞傷害性t細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン |
KR20110053836A (ko) * | 2009-11-16 | 2011-05-24 | 삼성에스디아이 주식회사 | 리튬 폴리머 이차 전지 |
AU2011313327B2 (en) | 2010-10-05 | 2015-10-22 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
WO2013002086A1 (ja) | 2011-06-28 | 2013-01-03 | 株式会社癌免疫研究所 | ペプチド癌抗原特異的t細胞のレセプター遺伝子 |
US9539299B2 (en) * | 2011-10-27 | 2017-01-10 | International Institute Of Cancer Immunology, Inc. | Combination therapy with WT1 peptide vaccine and temozolomide |
EP2776451B1 (en) | 2011-11-11 | 2018-07-18 | Fred Hutchinson Cancer Research Center | Cyclin a1-targeted t-cell immunotherapy for cancer |
US20150104413A1 (en) | 2012-01-13 | 2015-04-16 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
CN104797711B (zh) | 2012-09-12 | 2018-09-21 | 株式会社癌免疫研究所 | 抗原特异性辅助性t细胞受体基因 |
SG10201705028WA (en) | 2012-12-17 | 2017-07-28 | Otsuka Pharma Co Ltd | Method for activating helper t cell |
US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
EP3769782A1 (en) | 2013-01-15 | 2021-01-27 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
CN103961701B (zh) | 2013-02-05 | 2018-09-14 | 日东电工株式会社 | 疫苗组合物 |
RU2687144C2 (ru) | 2013-02-05 | 2019-05-07 | Нитто Денко Корпорейшн | Композиция противораковой вакцины, содержащей пептид wt1, для трансдермального введения |
CA2840974A1 (en) | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Vaccine composition for mucosal administration |
KR102050931B1 (ko) | 2013-02-05 | 2019-12-02 | 닛토덴코 가부시키가이샤 | 경피 투여용 wt1 펩티드 암 백신 테이프제 |
CN103961699B (zh) | 2013-02-05 | 2018-11-06 | 日东电工株式会社 | 经皮给予用wt1肽癌症疫苗组合物 |
CA2840937A1 (en) | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Vaccine composition for transdermal administration |
EP2762157A1 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | Vaccine composition for transdermal or mucosal administration |
RU2687026C2 (ru) | 2013-02-05 | 2019-05-06 | Нитто Денко Корпорейшн | Вакцинная композиция против злокачественной опухоли на основе пептида wt1 для мукозального введения |
US10023841B2 (en) * | 2014-05-23 | 2018-07-17 | Baylor Research Institute | Methods and compositions for treating breast cancer with dendritic cell vaccines |
CA2956545A1 (en) | 2014-08-04 | 2016-02-11 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for wt-1 |
EP3238744A4 (en) | 2014-12-25 | 2018-09-26 | International Institute of Cancer Immunology, Inc. | Method for modifying t cell population |
CN106610423A (zh) * | 2015-10-26 | 2017-05-03 | 复旦大学 | 评价疫苗疗效的细胞免疫学检测试剂盒及其储存方法 |
JP6994201B2 (ja) | 2016-11-09 | 2022-02-21 | 国立大学法人大阪大学 | T細胞集団の改変方法 |
EP3647433B1 (en) * | 2017-06-30 | 2023-04-12 | Osaka University | Method for predicting effect of tumor immunotherapy using tumor cytotoxic activity of peripheral blood t cells as index |
CN114555790A (zh) | 2019-08-20 | 2022-05-27 | 弗雷德哈钦森癌症研究中心 | Wt-1特异性t细胞免疫疗法 |
CN111978375B (zh) * | 2020-08-28 | 2022-10-04 | 深圳市乐土生物医药有限公司 | 具有细胞毒性t细胞诱导能力的蛋白质或多肽 |
CN112250752B (zh) * | 2020-12-21 | 2021-03-26 | 中生康元生物科技(北京)有限公司 | 肿瘤新抗原表位肽及其应用 |
JP2024500189A (ja) | 2020-12-21 | 2024-01-04 | アロジーン セラピューティクス,インコーポレイテッド | プロテアーゼ活性化cd45ゲートcar |
JP2024505075A (ja) | 2021-01-29 | 2024-02-02 | アロジーン セラピューティクス,インコーポレイテッド | 同種細胞産物のT細胞認識を軽減するための、TAP2、NLRC5、β2m、TRAC、RFX5、RFXAP及びRFXANKのうち1つ以上のノックダウン又はノックアウト |
US20240042030A1 (en) | 2022-07-29 | 2024-02-08 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
WO2000006602A1 (fr) | 1998-07-31 | 2000-02-10 | Haruo Sugiyama | Antigenes contre le cancer a base d'un produit du gene suppresseur de tumeur wt1 |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
IL142216A0 (en) | 1998-09-30 | 2002-03-10 | Corixa Corp | A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same |
GB9823897D0 (en) | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
WO2001025273A2 (en) * | 1999-10-04 | 2001-04-12 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
US20030082194A1 (en) * | 2000-02-22 | 2003-05-01 | Alexander Gaiger | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
BRPI0208183B8 (pt) | 2001-03-22 | 2021-05-25 | Sugiyama Haruo | peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer |
US20050002951A1 (en) | 2001-09-28 | 2005-01-06 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
US8735357B2 (en) | 2001-09-28 | 2014-05-27 | International Institute Of Cancer Immunology, Inc. | Method of inducing antigen-specific T cells |
AU2003242305A1 (en) | 2002-06-12 | 2003-12-31 | Chugai Seiyaku Kabushiki Kaisha | Hla-a24-restricted cancer antigen peptide |
EP1550453B1 (en) | 2002-09-12 | 2015-05-27 | International Institute of Cancer Immunology, Inc. | Cancer antigen peptide preparation |
WO2004026897A1 (ja) | 2002-09-20 | 2004-04-01 | Chugai Seiyaku Kabushiki Kaisha | Wt1置換型ペプチド |
AU2004204031B2 (en) | 2003-01-15 | 2010-03-04 | International Institute Of Cancer Immunology, Inc. | Dimerized peptide |
KR101292971B1 (ko) | 2003-06-27 | 2013-08-12 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Wt1 백신 적응 환자의 선택 방법 |
CN100513563C (zh) | 2003-11-05 | 2009-07-15 | 株式会社国际癌症免疫研究所 | Wt1衍生的hla-dr-结合抗原肽 |
WO2005095598A1 (ja) * | 2004-03-31 | 2005-10-13 | International Institute Of Cancer Immunology, Inc. | Wt1由来の癌抗原ペプチド |
-
2005
- 2005-03-30 WO PCT/JP2005/006113 patent/WO2005095598A1/ja not_active Application Discontinuation
- 2005-03-30 PL PL05727848T patent/PL1731605T3/pl unknown
- 2005-03-30 ES ES10152702.6T patent/ES2556232T3/es active Active
- 2005-03-30 EP EP10152702.6A patent/EP2186896B1/en active Active
- 2005-03-30 ES ES05727848T patent/ES2341785T3/es active Active
- 2005-03-30 JP JP2006511744A patent/JP4886507B2/ja active Active
- 2005-03-30 PT PT05727848T patent/PT1731605E/pt unknown
- 2005-03-30 AT AT05727848T patent/ATE462003T1/de active
- 2005-03-30 DK DK10152702.6T patent/DK2186896T3/da active
- 2005-03-30 SI SI200530954T patent/SI1731605T1/sl unknown
- 2005-03-30 EP EP05727848A patent/EP1731605B1/en not_active Not-in-force
- 2005-03-30 US US10/594,507 patent/US7622119B2/en not_active Expired - Fee Related
- 2005-03-30 DE DE602005020121T patent/DE602005020121D1/de active Active
- 2005-03-30 DK DK05727848.3T patent/DK1731605T3/da active
-
2009
- 2009-09-04 US US12/554,151 patent/US8388975B2/en active Active
-
2010
- 2010-11-17 HK HK10110703.5A patent/HK1144305A1/zh not_active IP Right Cessation
-
2013
- 2013-01-24 US US13/748,984 patent/US20130196427A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PL1731605T3 (pl) | 2010-08-31 |
JP4886507B2 (ja) | 2012-02-29 |
US20100062013A1 (en) | 2010-03-11 |
JPWO2005095598A1 (ja) | 2008-02-21 |
DK2186896T3 (da) | 2015-12-21 |
US20080152631A1 (en) | 2008-06-26 |
WO2005095598A1 (ja) | 2005-10-13 |
EP1731605A1 (en) | 2006-12-13 |
SI1731605T1 (sl) | 2010-07-30 |
EP2186896B1 (en) | 2015-11-04 |
EP1731605B1 (en) | 2010-03-24 |
ES2556232T3 (es) | 2016-01-14 |
US7622119B2 (en) | 2009-11-24 |
ATE462003T1 (de) | 2010-04-15 |
US20130196427A1 (en) | 2013-08-01 |
DE602005020121D1 (de) | 2010-05-06 |
EP2186896A1 (en) | 2010-05-19 |
HK1144305A1 (zh) | 2011-02-11 |
ES2341785T3 (es) | 2010-06-28 |
PT1731605E (pt) | 2010-04-14 |
EP1731605A4 (en) | 2007-11-07 |
US8388975B2 (en) | 2013-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1731605T3 (da) | Cancerantigenpeptider der er afledt af WT1 | |
NL301089I2 (nl) | imlifidase | |
NO20063624L (no) | FC region varianter | |
ATE428727T1 (de) | Neue, an den erythropoietinrezeptor bindende peptide | |
DE60310731D1 (de) | Neue, von noraporphin abgeleitete moleküle | |
EA200701825A1 (ru) | Вакцины против хламидиоза | |
RU2013119417A (ru) | Антигенсвязывающие молекулы, которые связывают egfr, кодирующие их векторы и их применение | |
EA201100868A1 (ru) | Противоопухолевые комбинации, содержащие антитела, специфически распознающие cd38, и цитарабин | |
CY1110980T1 (el) | Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες | |
EA201070271A1 (ru) | Пептиды для получения вакцины | |
DK1625156T3 (da) | Peptider, der bindes til erythropoietinreceptoren | |
ZA200705943B (en) | Survivin peptide vaccine | |
NO20052149D0 (no) | Vaksine. | |
EA200801180A1 (ru) | Селективные пептидные агонисты рецептора vpac2 | |
DE602005007364D1 (de) | Peptidcyclisierung | |
ATE446314T1 (de) | Methode zur reinigung von fsh | |
AP2415A (en) | Bacteriocin Inducer peptides. | |
DK1628989T3 (da) | Hidtil ukendte, 14- og 15-leddet ring-forbindelser | |
ITMI20030107A1 (it) | Peptidi derivati da rantes. | |
DE602007006493D1 (de) | Peptide mit proliferationshemmender wirkung | |
ITRM20040489A1 (it) | Pentraxina lunga ptx3 deglicosilata o desialidata. | |
DE602004012207D1 (de) | Fluoreszent markierte Ghrelin-Peptide | |
CY1116106T1 (el) | Μεθοδος προληψης ή θεραπεια μολυνσης m. tuberculosis | |
ITRM20050128A1 (it) | Peptidi immunogeni anti-tumorali e relativi vaccini. | |
ITMI20031904A1 (it) | Lampada abbronzante. |